Posts

Showing posts with the label aseptic process

Pharmaceutical Implications of Emerging Pathogens : Challenges and Strategies

Pharmaceutical Implications of Emerging Pathogens: Challenges and Strategies in Drug Development The rise of emerging pathogens poses unprecedented challenges to the pharmaceutical industry. These pathogens, which include novel viruses, bacteria, and fungi, threaten drug safety, product quality, and supply chain integrity. Understanding their implications is critical for ensuring regulatory compliance , patient safety, and effective drug development. 🔬 What Are Emerging Pathogens? Emerging pathogens are microorganisms whose incidence in humans or animals has increased in recent decades or threatens to increase in the near future. Examples include: Antibiotic-resistant bacteria: MRSA, Carbapenem-resistant Enterobacteriaceae (CRE) Fungal pathogens: Candida species, Aspergillus species These pathogens can enter pharmaceutical processes through raw materials, personnel, or environmental contamination, potentially compromising sterile and non-sterile products...

Popular posts from this blog

Too Numerous To Count (TNTC) & Too Few To Count (TFTC) in Microbiology: Meaning, Limits, Calculations, and GMP Impact

Non-Viable Particle Count (NVPC) in Cleanrooms: Principles, Methods & GMP Requirements

USP 41; Balances Explained (2026): Measurement Uncertainty, Minimum Weight, Audit Readiness; Why USP Revised the Rule